Full-Time

Head of Clinical Pharmacology and Pharmacometrics

Confirmed live in the last 24 hours

Insmed

Insmed

501-1,000 employees

Develops therapies for rare diseases

Compensation Overview

$247k - $345.5k/yr

+ Bonus + Equity Awards

Expert

United States

Hybrid work model; specific in-office days not mentioned.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • PhD or MD in Clinical Pharmacology, Pharmacometrics, Pharmacokinetics, or related field.
  • 10+ years of relevant industry experience in clinical pharmacology/pharmacometrics with demonstrated leadership in advancing drug development programs.
  • Strong track record in global regulatory interactions, including successful INDs, NDAs, or CTAs.
  • Deep understanding of clinical pharmacology principles and regulatory requirements across therapeutic areas.
  • Proven ability to influence cross-functional teams and senior partners in a matrixed environment.
  • Outstanding problem-solving, organizational, and communication skills.
Responsibilities
  • Oversee the development and implementation of innovative CPP strategies for drug development programs, including dose selection, study design, and lifecycle management.
  • Partner with cross-functional teams, including Biostatistics, Clinical Operations, Regulatory, CMC, Clinical, and Translational Biomarkers/Bioanalyticals to align clinical pharmacology objectives with program goals.
  • Represent the CPP function at internal forums and in health authority interactions.
  • Oversee the design, analyses, and interpretation of PK/PD, exposure-response, population PK, and quantitative modeling to inform decision-making for clinical trials.
  • Oversee Clinical Pharmacology aspects of regulatory submissions, including INDs, NDAs, CTAs, and health authority responses.
  • Ensure clinical pharmacology strategies and deliverables meet global regulatory requirements.
  • Lead preparation of pharmacology components for regulatory documents and participate in regulatory meetings.
  • Actively participate in cross-functional team meetings and provide expertise in integrating pre-clinical and clinical data.
  • Present findings and recommendations to internal partners, senior leadership, and external collaborators.
  • Drive external partnerships with CROs, consultants, and academic institutions.
  • Build, mentor, and lead a high-performing CPP team, encouraging innovation, scientific rigor, and professional development.
  • Oversee deliverables of direct reports and external collaborators to maintain high scientific and ethical standards.

Insmed develops therapies for patients with serious and rare diseases. The company focuses on unmet medical needs and has a pipeline of clinical trials and approved treatments. Its products are created through extensive research and development, followed by regulatory approvals before they can be sold. Insmed operates globally, with headquarters in Bridgewater, NJ, and offices in Europe and Japan. What sets Insmed apart from competitors is its strong commitment to patient care and its ability to address various healthcare challenges through its global infrastructure. The goal of Insmed is to provide effective treatments for patients suffering from rare diseases.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Richmond, Virginia

Founded

1988

Simplify Jobs

Simplify's Take

What believers are saying

  • ARIKAYCE's revenue is projected to grow double digits in 2025.
  • Brensocatib's NDA submission could lead to a US launch by Q3 2025.
  • Gene therapy advancements position Insmed for breakthroughs in rare disease treatment.

What critics are saying

  • Increased competition in rare diseases could impact Insmed's market share.
  • High clinical trial costs may strain Insmed's financial resources.
  • Regulatory approval delays could affect Insmed's product launch timelines.

What makes Insmed unique

  • Insmed focuses on rare diseases with unmet medical needs, setting it apart.
  • The company integrates AI-driven protein engineering for precise drug discovery.
  • Insmed's global presence in the US, Europe, and Japan enhances its market reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Health Insurance

Paid Vacation

Employee Stock Purchase Plan

Company Equity

Company News

ETF Daily News
Mar 7th, 2025
Proficio Capital Partners LLC Invests $1.86 Million in Insmed Incorporated (NASDAQ:INSM)

Proficio Capital Partners LLC invests $1.86 million in Insmed Incorporated (NASDAQ:INSM).

PR Newswire
Feb 7th, 2025
Insmed Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BRIDGEWATER, N.J., Feb. 7, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 66 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.In connection with the commencement of their employment, the employees received options on February 3, 2025 to purchase an aggregate 108,860 shares of Insmed common stock at an exercise price of $77.88 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.About InsmedInsmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan

PR Newswire
Jan 10th, 2025
Insmed Provides Business Update At 43Rd Annual J.P. Morgan Healthcare Conference

--ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million----2025 Global ARIKAYCE Revenues Expected to be Between $405 Million and $425 Million, Reflecting Continued Double-Digit Growth Compared to 2024----NDA for Brensocatib in Bronchiectasis Submitted to FDA in December 2024, Narrowing the Timing for Expected U.S. Launch to the Third Quarter of 2025, Pending Approval Under Priority Review----Enrollment for Phase 2 Study of TPIP in Patients with PAH Completed in December 2024; Expected Timing for Topline Data Moved Forward to Mid-2025----Phase 3 ENCORE Trial for ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Disease Fully Enrolled; Topline Data Anticipated in First Quarter of 2026----IND Cleared for Insmed's First Gene Therapy (INS1201) for Patients with DMD; First Patient Dosing Anticipated in the First Half of 2025--BRIDGEWATER, N.J., Jan. 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today provided an update on the Company's commercial and clinical programs and its outlook for 2025. These updates will be discussed as part of the Company's presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13, 2025, at 3:00 p.m. PT (6:00 p.m

PR Newswire
Jan 3rd, 2025
Insmed Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BRIDGEWATER, N.J., Jan. 3, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 19 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.In connection with the commencement of their employment, the employees received options on January 2, 2025, to purchase an aggregate 65,930 shares of Insmed common stock at an exercise price of $69.95 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.About InsmedInsmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan

Stock Titan
Jan 2nd, 2025
Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Insmed (Nasdaq: INSM) has announced its management team will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.